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Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-
circulated in Europe in 2014/15. We undertook a multi-
centre case–control study in eight European countries 
to measure 2014/15 influenza vaccine effectiveness 
(VE) against medically-attended influenza-like ill-
ness (ILI) laboratory-confirmed as influenza. General 
practitioners swabbed all or a systematic sample of 
ILI patients. We compared the odds of vaccination of 
ILI influenza positive patients to negative patients. 
We calculated adjusted VE by influenza type/subtype, 
and age group. Among 6,579 ILI patients included, 
1,828 were A(H3N2), 539 A(H1N1)pdm09 and 1,038 B. 
VE against A(H3N2) was 14.4% (95% confidence inter-
val (CI): -6.3 to 31.0) overall, 20.7% (95%CI: -22.3 to 
48.5), 10.9% (95%CI -30.8 to 39.3) and 15.8% (95% 
CI: -20.2 to 41.0) among those aged 0–14, 15–59 
and   ≥60  years, respectively. VE against A(H1N1)
pdm09 was 54.2% (95%CI: 31.2 to 69.6) overall, 73.1% 
(95%CI: 39.6 to 88.1), 59.7% (95%CI: 10.9 to 81.8), and 
22.4% (95%CI: -44.4 to 58.4) among those aged 0–14, 
15–59 and   ≥60 years respectively. VE against B was 
48.0% (95%CI: 28.9 to 61.9) overall, 62.1% (95%CI: 
14.9 to 83.1), 41.4% (95%CI: 6.2 to 63.4) and 50.4% 
(95%CI: 14.6 to 71.2) among those aged 0–14, 15–59 
and ≥60 years respectively. VE against A(H1N1)pdm09 
and B was moderate. The low VE against A(H3N2) is 
consistent with the reported mismatch between circu-
lating and vaccine strains.
Introduction
In February 2014 each year, the World Health 
Organization (WHO) provides recommendations for 
the composition of the northern hemisphere vac-
cines, based on information from the WHO Global 
Influenza Surveillance and Response System. In 2014, 
the WHO vaccine strain selection committee recom-
mended that the 2014/15 northern hemisphere influ-
enza vaccine should include the same components as 
in 2013/14: an A/California/7/2009 (H1N1)pdm09-like 
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Figure 1
Flowchart of data exclusion for pooled analysis, I-MOVE multicentre case–control study, Europe, influenza season 2014/15 
(week 41/2014-week 19/2015)
• Patients with contraindications against vaccination (n=0)
• Patients administered antivirals prior to swabbing (n=8)
• Patients with missing lab results (n=10)
• Patients with missing onset date (n=236)
• With date of onset of symptoms <15 days after begin of vaccination campaign (n=3)
• Not meeting the EU ILI case definition (n=859) or EU ILI status unknown (n=98)
• With interval between onset of symptoms and swabbing >7 days (n=137)
• Excluding patients presenting before ISO week of any influenza case and after ISO week of last influenza case 
   after which there are two consecutive weeks of no cases (weeks of symptom onset, by country) (n=62)
N=6,579 ; cases of any influenza: 3,437;  controls: 3,142
• Dropping influenza-positive records of different type/subtype
• Excluding patients presenting before ISO week of first type/subtype-specific influenza case and after ISO week 
   of last type/subtype-specific influenza case after which there are two consecutive weeks of no cases (weeks of 














Dropping records with missing data for complete case analysis
Records with missing vaccination brand for vaccine group analysis
Number of records received for pooled analysis
7,992
Influenza A(H3N2)  analysis Influenza A(H1N1) pdm09 analysis Influenza B analysis
• Persons with missing 2014/15 influenza vaccination  status or date




























Influenza A(H3N2)  analysis Influenza A(H1N1) pdm09 analysis Influenza B analysis
EU: European Union; ILI: influenza-like illness; I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe; ISO: International Organization for 
Standardization.
a Includes 15 influenza B + A(H3N2) co-infections.
b Includes 8 influenza B + A(H1N1)pdm09 co-infections.
c Includes 3 influenza B + A(H3N2)pdm09, and 7 A(H1N1)pdm09 + A(H3N2) co-infections.
d Includes 14 influenza B + A(H3N2)pdm09 co-infections.
e Includes 7 influenza B + A(H1N1)pdm09 co-infections.
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Figure 2
Number of influenza-like illness reports by case status and week of symptom onset, all influenza, target groups for 




















ISO week of onset of symptoms
Influenza negative ILI (n=3,142) Influenza A (H3N2) (n=1,828)
Influenza B (n=1,038)Influenza A (H1N1)pdm09  (n=539)
ILI: influenza-like illness; I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe, ISO: International Organization for Standardization.
a This includes 15 influenza B + A(H3N2) co-infections and eight influenza B + A(H1N1)pdm09 co-infections. Note that numbers of cases come 
from influenza type/subtype specific databases. Some cases are excluded due to their restriction criteria. Any influenza A non-typed cases 
are dropped from analysis.
The proportion vaccinated with the 2014/15 influenza vaccine was 13.2% among controls, 13.0% among A(H3N2) cases, 6.9% among A(H1N1)
pdm09 cases and 7.4% among B cases (Table 2).
Figure 3
Pooled crude and adjusted seasonal vaccine effectiveness against laboratory confirmed influenza by influenza type/subtype, 


























































I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe.
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virus, an A/Texas/50/2012 (H3N2)-like virus, and a B/
Massachusetts/2/2012-like virus [1].
In September 2014, the WHO reported the emergence 
of two new influenza virus genetic clades for A(H3N2), 
clade 3C.2a and 3C.3a [1]. These clades had first cir-
culated in Europe during the 2013/14 influenza season 
[2].
In December 2014, the United States (US) Centers for 
Disease Control and Prevention (CDC) issued a Health 
Alert reporting that 52% of the A(H3N2) viruses circu-
lating were antigenically different from the A(H3N2) 
component of the northern hemisphere 2014/15 influ-
enza vaccine. CDC recommended the use of antiviral 
medications where indicated for the treatment and 
prevention of influenza, as an adjunct to vaccination 
[3]. Concordant with the reports of the drifted A(H3N2) 
viruses, in January 2015, the US, Canada and the United 
Kingdom (UK) reported low influenza vaccine effec-
tiveness (VE) against A(H3N2) [4-6]. Canadian results 
suggested that VE against influenza A(H3N2) among 
individuals who had been vaccinated in both 2013/14 
and 2014/15 seasons was lower than among those who 
were only vaccinated in 2014/15 [5].
In Europe, the influenza season started later than in 
the US and Canada. Increased influenza activity in 
Europe was first reported in early January 2015, with 
a predominance of A(H3N2) but with influenza A(H1N1)
pdm09 and B circulating as well [7].
For this seventh season of the Influenza Monitoring 
Vaccine Effectiveness in Europe (I-MOVE) multicentre 
case–control study we aimed to measure the 2014/15 
effectiveness of the seasonal influenza vaccine against 
the three co-circulating viruses by age group and by 
vaccine type. In addition, due to the potential implica-
tions for vaccination policy we explored the effect of 
previous vaccinations on the current season VE.
Methods
Eight study sites (Germany, Hungary, Ireland, Italy, 
Poland, Portugal, Romania and Spain) participated in 
the test-negative 2014/15 multicentre case–control 
study. The methods have been described previously 
[7-9] and are based on the European Centre for Disease 
Prevention and Control (ECDC) generic case–control 
study protocol [10].Briefly, participating general prac-
titioners (GPs) interviewed and collected naso-phar-
yngeal specimens from all (seven study sites) or a 
systematic sample (in Germany) of patients consult-
ing for influenza- like illness (ILI) aged 60 (Germany, 
Poland, and three regions in Spain) or 65 years old 
(Hungary, Ireland, Italy, Portugal, Romania and three 
regions in Spain) and older and from a systematic sam-
ple of ILI patients in the other age groups. In Hungary, 
only patients aged 18 years or over were eligible for 
inclusion in the study. GPs collected clinical and epide-
miological information as previously described [8]. We 
included patients in the study who presented to the GPs 
more than 14 days after the start of the national vac-
cination campaigns and who met the European Union 
(EU) ILI case definition [11], were swabbed within seven 
days of symptom onset, and who had not received anti-
virals before swabbing.
Cases were ILI patients who were swabbed and tested 
positive for influenza virus using real-time reverse-tran-
scription PCR (RT-PCR). Controls were ILI patients who 
tested negative for any influenza virus using RT-PCR. 
Cases and controls were not included in the influenza 
type/subtype-specific analyses if fewer than five type/
subtype-specific cases were reported by study site. 
Influenza A cases of unknown subtype were excluded 
from the analysis.
For each study site and for each influenza type/sub-
type, the study period started on the week of onset 
of the first influenza case recruited and ended on the 
week of onset of the last influenza case after which 
there were at least two consecutive weeks with no fur-
ther influenza positive cases.
We defined a patient as vaccinated if they had received 
minimum one dose of 2014/15 influenza vaccine at 
least 15 days before ILI symptom onset. We consid-
ered all other patients unvaccinated. GPs ascertained 
vaccination based on vaccination records or patient’s 
self-report.
For each study site, we compared the odds of vacci-
nation in cases and controls calculating the odd ratio 
(OR). We conducted a complete case analysis excluding 
patients with missing values for any of the variables in 
the model measuring adjusted VE. We carried out a 
one-stage model with study site as a fixed effect. We 
used Cochran’s Q-test and the I2 index to test the het-
erogeneity between study sites [12].
We used a logistic regression model to calculate VE 
including potential confounding factors: age (mod-
elled as a restricted cubic spline with four knots or age 
group as a categorical variable depending on the anal-
ysis), sex, presence of at least one underlying chronic 
condition (including pregnancy and obesity where 
available) and date of symptom onset (modelled as a 
restricted cubic spline with four knots where sample 
size allowed).
To study the effect of 2013/14 vaccination on the 
2014/15 VE, we conducted a stratified analysis using 
four categories: individuals unvaccinated in both sea-
sons (reference category), vaccinated in 2013/14 only, 
vaccinated in 2014/15 only, and those vaccinated in 
both seasons.
We measured VE by age group (0–14, 15–59 and ≥60 
years) and by type of vaccine (adjuvanted, egg-derived 
inactivated subunit, cell-derived inactivated subu-
nit, egg-derived inactivated split virion). We excluded 
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Figure 4
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Details of influenza haemagglutinin sequences obtained from GISAID used in the phylogenetic analysis, I-MOVE 
multicentre case–control study, Europe, influenza season 2014/15 (week 41/2014-week 19/2015)
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GISAID: Global Initiative on Sharing Avian Influenza Data.
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study sites from the vaccine type analysis, where the 
given type of vaccine was not available.
We conducted four sensitivity analyses (i) restricting 
the study to patients swabbed less than 4 days after 
symptom onset, (ii) restricting to the population tar-
geted for vaccination as defined in each country [23] 
(iii) excluding patients vaccinated < 15 days after symp-
tom onset, (iv) calculating adjusted VE using a two-
stage model using random effects.
The respective country’s National Influenza Reference 
Laboratories tested swab specimens for influenza 
by real-time RT-PCR assays. In Spain, other laborato-
ries participating in the National Influenza Sentinel 
Surveillance System tested specimens. In each study 
site, a non-random selection of positive specimens 
or isolated viruses from positive specimens were 
subsequently sent to the corresponding National 
Influenza Centre, where influenza diagnosis was con-
firmed and viruses characterised either by sequenc-
ing the HA1 coding portion of the haemagglutinin gene 
(genetic characterisation) or by haemagglutination 
inhibition (antigenic characterisation). The criteria to 
select the specimens for genetic and antigenic charac-
terisation varied by study site.
For the I-MOVE pooled analysis, the Spanish and 
Portuguese National Influenza Centres analysed the nt 
and amino acid sequences of the HA1 coding portion 
of the haemagglutinin gene and used the neighbour-
joining method and the Kimura 2-parameter nt substi-
tution model for phylogenetic analysis. A phylogenetic 
tree was constructed with a bootstrap analysis of 500 
replicates (values above 50 are shown) using MEGA 
software version 6 (Tamura, Stecher, Peterson, Filipski, 
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GISAID: Global Initiative on Sharing Avian Influenza Data.
Table 1 b
Details of influenza haemagglutinin sequences obtained from GISAID used in the phylogenetic analysis, I-MOVE 
multicentre case–control study, Europe, influenza season 2014/15 (week 41/2014-week 19/2015)
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and Kumar 2013). HA sequences from reference strains 
used in the phylogenetic analysis were obtained from 
the EpiFlu database of the Global Initiative on Sharing 
Avian Influenza Data (GISAID) (Table 1).
Results
Within the I-MOVE multicentre case–control study, the 
start of country-specific study periods ranged from 
week 41, 2014 (Germany) to week 3, 2015 (Poland), 
and the end from week 13, 2015 (Portugal) to week 19, 
2015 (Germany). Study period duration ranged from 14 
(Poland) to 31 (Germany) weeks.
Among the 7,992 ILI patients recruited, 6,579 ILI 
patients met the eligibility criteria including 3,142 test-
ing negative for all influenza viruses. For the influenza 
type/subtype-specific analysis datasets, we included 
1,828 influenza A(H3N2), 1,038 influenza B, 539 influ-
enza A(H1N1)pdm09 (Figure 1).
The median onset date was 1 February for A(H1N1)
pdm09, 1 February for A(H3N2), and 20 February for B 
cases (Figure 2). Forty-one percent of A(H3N2) cases 
were recruited in Germany, 44% of A(H1N1)pdm09 in 
Italy and 30% of B cases in Spain.
The median age was higher in influenza B cases (39 
years) compared with influenza A(H3N2) and A(H1N1) 
cases (28 and 30 years respectively) and controls (31 
years).
The proportion of patients swabbed more than three 
days after ILI onset was 15.9% among controls, and 
10.3%, 13.5% and 15.9% among A(H3N2), A(H1N1)
pdm09 and B cases respectively.
The proportion of patients belonging to the target 
group for vaccination, or with at least one chronic con-
dition or with at least one hospitalisation in the previ-
ous 12 months was similar between influenza A(H3N2), 
A(H1N1)pdm09, B cases and controls.
Nine percent of controls, and 11%, 5% and 6% of 
A(H3N2), A(H1N1)pdm09 and B cases had received 
both the 2013/14 and the 2014/15 vaccines.
Of the 735 vaccinated individuals, 620 (84%) had 
information on the vaccine type received; they were 
vaccinated with ten different brands. By vaccine type, 
40% had received egg-derived inactivated subunit 
(used in all sites except in Hungary and Italy), 33% 
egg-derived inactivated split virion (used in all sites 
except in Ireland and Romania), 21% adjuvanted (used 
in Germany, Hungary, Italy and Spain) and 5% cell-
derived inactivated subunit vaccines (used in Germany 
and Spain).
After excluding patients with missing information 
(n = 833; 7%), we included 4,491, 2,920 and 3,730 
patients in the complete case analysis of VE against 
influenza A(H3N2), A(H1N1)pdm09 and B respectively 
(Figure 1).
The I2 was < 50% (p > 0.05) when assessing crude type/
subtype specific VE by study site and age group. 
Sample size among the 0–14 year-olds for the A(H1N1)
pdm09 analysis was too small to carry out tests for het-
erogeneity. When assessing crude VE against A(H3N2) 
by study site among the target group for vaccination, 
the I2 was 61.5% (p = 0.016).
Influenza A(H3N2)
The overall adjusted VE against influenza A(H3N2) was 
14.4% (95% CI: -6.3 to 31.0) (Table 3).
Adjusted VE was 20.7% (95% CI: -22.3 to 48.5) among 
the 0–14 year olds, 10.9% (95% CI: -30.8 to 39.3) 
among the 15–59 year olds and 15.8% (95% CI: -20.2 
to 41.0) among those ≥60 years. By vaccine type, the 
adjusted VE point estimates were lower for cell-derived 
inactivated subunit vaccines (-9.3%) compared with 
egg-derived inactivated subunit, egg-derived inacti-
vated split virion, and adjuvanted vaccines (10.9%, 
18.6% and 14.0% respectively) (Table 4).
The adjusted VE was 43.7% (95% CI: 15.3 to 62.5) 
among those vaccinated in 2014/15 only, 0.0% (95%CI: 
-50.7 to 33.7) among those vaccinated in 2013/14 only, 
and -5.2% (95%CI: -34.3 to 17.6) among those vacci-
nated in both seasons (Table 4, Figure 3).
The overall adjusted VE point estimate was similar to 
the adjusted VE among those swabbed less than 4 
days of symptom onset (17.4%) and to the adjusted 
VE excluding individuals vaccinated less than 15 days 
after symptom onset (13.7%). The adjusted VE point 
estimate was higher when restricting the analysis to 
the target population (26.2%) (Table 2). The adjusted 
VE estimates using a two-stage random effects model 
were similar (within 6 % points) to the one-stage 
pooled analysis VE for all population and restricted 
to the target group for vaccination (Table 2). The two-
stage VE point estimate in the  ≥60  year- olds was 10% 
higher than the one-stage VE but three study sites were 
excluded from the two-stage analysis due to their lim-
ited sample size.
One hundred and fourteen (6%) of the 1,828 A(H3N2) 
viruses included in the analysis were genetically or 
antigenically characterised. Seventy-five viruses of 
the 114 (66%) were antigenically distinct from the 
vaccine virus A/Texas/50/2012: 58 belonged to clade 
3C.2a, represented by A/HongKong/5738/2014, 
and 17 belonged to clade 3C.3a represented by A/
Switzerland/9715293/2013 (Table 5).
Of the 114 characterised A(H3N2) viruses, 107 (94%) 
were sequenced. Compared with A/Texas/50/2012, 
17 viruses had the T128A, R142G and N145S muta-
tions that define the group 3.C represented by A/
Samara/73/2013. Eight viruses had in addition the 
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Table 2
Details for influenza, A(H3N2), A(H1N1)pdm09 and influenza B cases and controls, I-MOVE multicentre case–control 
study, Europe, influenza season 2014/15 (week 41/2014-week 19/2015) (n=6,524a)
Variables
Number of test-negative 
controls /total n(%) 
(n=3,142) b
Number of influenza A(H3N2) 
cases /total n(%) 
(n=1,828)c
Number of influenza A(H1N1)
pdm09 /total n(%) 
(n=1,038)d
Number of influenza 
B cases /total n(%) 
(n=539) c,d
Median age (years) 31.0 28.0 30.0 39.0
Missing 5 1 1 0
Age groups 
0–4 years 620/3,137 (19.8) 212/1,827 (11.6) 136/538 (25.3) 62/1,038 (6)
5–14 years 459/3,137 (14.6) 451/1,827 (24.7) 85/538 (15.8) 219/1,038 (21.1)
15–59 years 1,539/3,137 (49.1) 885/1,827 (48.4) 256/538 (47.6) 619/1,038 (59.6)
 ≥ 60 years 519/3,137 (16.5) 279/1,827 (15.3) 61/538 (11.3) 138/1,038 (13.3)
Missing 5 1 1 0
Sex 
Female 1,610/3,132 (51.4) 945/1,825 (51.8) 283/539 (52.5) 556/1,037 (53.6)
Missing 10 3 0 1
Days between onset of symptoms and swabbing 
0 254/3,142 (8.1) 128/1,828 (7) 55/539 (10.2) 32/1,038 (3.1)
1 1,076/3,142 (34.2) 662/1,828 (36.2) 206/539 (38.2) 286/1,038 (27.6)
2 816/3,142 (26) 574/1,828 (31.4) 128/539 (23.7) 317/1,038 (30.5)
3 497/3,142 (15.8) 275/1,828 (15) 77/539 (14.3) 238/1,038 (22.9)
4–7 499/3,142 (15.9) 189/1,828 (10.3) 73/539 (13.5) 165/1,038 (15.9)
Seasonal vaccination, 2014/15e 392/2,978 (13.2) 228/1,759 (13.0) 36/522 (6.9) 75/1,010 (7.4)
Missing 164 69 17 28
Previous season influenza vaccination 
Not vaccinated or vaccinated < 15 days before 
onset 2,432/2,918 (83.3) 1,461/1,733 (84.3) 464/515 (90.1) 901/1,001 (90)
Current season vaccination only 98/2,918 (3.4) 41/1,733 (2.4) 10/515 (1.9) 14/1,001 (1.4)
Previous season vaccination only 113/2,918 (3.9) 47/1,733 (2.7) 15/515 (2.9) 27/1,001 (2.7)
Current and previous season vaccination 275/2,918 (9.4) 1,84/1,733 (10.6) 26/515 (5.0) 59/1,001 (5.9)
Missing 224 95 24 37
2014/15 vaccine type 
Not vaccinated or vaccinated < 15 days before 
onset 2,586/2,978 (82.3) 1,531/1,759 (83.8) 486/522 (90.2) 935/1,010 (90.1)
Egg-derived inactivated subunit 124/2,978 (3.9) 89/1,759 (4.9) 10/522 (1.9) 27/1,010 (2.6)
Egg-derived inactivated split virion 115/2,978 (3.7) 56/1,759 (3.1) 16/522 (3) 19/1,010 (1.8)
Adjuvanted 81/2,978 (2.6) 38/1,759 (2.1) 3/522 (0.6) 8/1,010 (0.8)
Cell- derived inactivated subunit 10/2,978 (0.3) 13/1,759 (0.7) 0/522 (0) 7/1,010 (0.7)
Unknown vaccine type 62/2,978 (2) 32/1,759 (1.8) 7/522 (1.3) 14/1,010 (1.3)
Missing vaccination status or date 164 69 17 28
At least one chronic condition 661/3,024 (21.9) 384/1,776 (21.6) 110/525 (21.0) 216/1,023 (21.1)
Missing 118 52 14 15
At least one hospitalisation in the previous 12 
months for chronic conditions 
56/3,100 (1.8) 25/1,806 (1.4) 7/534 (1.3) 23/1,033 (2.2)
Missing 42 22 5 5
Belongs to target group for vaccination 902/3,069 (29.4) 511/1,801 (28.4) 141/530 (26.6) 301/1,029 (29.3)
Missing 73 27 9 9
Study sites 
Germany 1,472/3,142 (46.8) 741/1,828 (40.5) 185/539 (34.3) 268/1,038 (25.8)
Ireland 109/3,142 (3.5) 102/1,828 (5.6) 11/539 (2) 57/1,038 (5.5)
Hungary 379/3,142 (12.1) 232/1,828 (12.7) 32/539 (5.9) 42/1,038 (4)
Portugal 102/3,142 (3.2) 45/1,828 (2.5) 0/539 (0) 98/1,038 (9.4)
Italy 594/3,142 (18.9) 229/1,828 (12.5) 237/539 (44) 123/1,038 (11.8)
Poland 77/3,142 (2.5) 18/1,828 (1) 21/539 (3.9) 70/1,038 (6.7)
Romania 76/3,142 (2.4) 80/1,828 (4.4) 43/539 (8) 73/1,038 (7)
Spain 333/3,142 (10.6) 381/1,828 (20.8) 10/539 (1.9) 307/1,038 (29.6)
I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe.
a This includes 15 influenza B + A(H3N2) co-infections and 8 influenza B + A(H1N1)pdm09 co-infections. Note that numbers of cases come from influenza type/subtype specific 
databases. Some cases are excluded due to their restriction criteria. Any influenza A non-typed cases are dropped from analysis.
b Controls from ’any influenza’ analysis used.
c Includes 15 influenza B + A(H3N2) co-infections.
d Includes 8 influenza B + A(H1N1)pdm09 co-infections.
e Vaccination more than 14 days before onset of influenza like illness symptoms.
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All ages 4,491 1,723;225/2,768;365 -1.9 -22.2 to 15.1 14.4 -6.3 to 31.0
0–14 years 1,505 607;54/898;64 -38.4 -103.5 to 5.9 20.7 -22.3 to 48.5
15–59 years 2,245 846;57/1,399;91 -2.2 -45.3 to 28.1 10.9 -30.8 to 39.3
 ≥60 years 741 270;114/471;210 7.3 -26.9 to 32.2 15.8 -20.2 to 41.0
Target group for vaccination 1,287 483;155 / 804;276 10.9 -14.5 to 30.6 26.2 1.6 to 44.7
Vaccinated  < 15 days excluded 4,475 1,718;225/2,757;365 -1.8 -22.2 to 15.1 13.7 -7.2 to 30.5
Restricted delay onset and 




All ages 4,503 1,724;225/2,779;366 -0.6 -31.2 to 22.8 9.0 -28.2 to 35.4
0–14e years 1,418 564;54/853;63 -42.2 -109.2 to 3.3 22.9 -20.7 to 50.8
15–59f years 2,192 853;57/1,357;88 -6.6 -53.2 to 25.8 12.3 -31.6 to 41.5
 ≥60g years 678 254;108/424;187 11.3 -24.9 to 37.1 25.5 -24.5 to 55.4





All ages 2,920 515;36/2,405;314 53.7 33.1 to 68.0 54.2 31.2 to 69.6
0–14 years 1,023 211;8/812;63 59.9 13.4 to 81.5 73.1 39.6 to 88.1
15–59 years 1,436 245;8/1191;75 47.5 -13.1 to 75.6 59.7 10.9 to 81.8
 ≥60 years 451 59;20/392;171 22.4 -44.4 to 58.4 22.4 -44.4 to 58.4
Target group for vaccination 832 138;26/694;232 53.8 26.0 to 71.2 53.6 22.1 to 72.3
Vaccinated < 15 days excluded 2,914 515;36/2,399;314 53.9 33.3 to 68.1 54.5 31.6 to 69.7
Restricted delay onset and 




All agesj 2,650 494;34/2,156;285 53.6 20.6 to 72.9 53.5 27.8 to 70.1
0–14k years 916 196;7/720;59 59.5 -79.6 to 90.9 71.6 20.5 to 89.9
15–59l years 941 195;7/746;52 35.4 -51.3 to 72.4 51.8 -15.9 to 79.9
 ≥60m years 290 41;18/249;120 15.8 -65.3 to 57.1 NA NA





All ages 3,730 1,001;74 / 2,729;362 47.9 31.3 to 60.4 48.0 28.9 to 61.9
0–14 years 1,143 269;11 / 874;62 37.8 -23.2 to 68.6 62.1 14.9 to 83.1
15–59 years 1,986 602;29 / 1,384;94 29.6 -10.3 to 55.0 41.4 6.2 to 63.4
≥60years 601 130;34 / 471;206 54.4 25.8 to 72.0 50.4 14.6 to 71.2
Target group for vaccination 1,083 290;56 / 793;273 54.6 35.2 to 68.2 49.8 26.2 to 65.9
Vaccinated  < 15 days excluded 3,719 998;74/2,721;362 47.8 31.3 to 60.4 47.8 28.6 to 61.8
Restricted delay onset and 




All ages 3,734 1,003;74/2,731;363 48.9 25.3 to 65.0 51.5 26.8 to 61.8
0–14p years 1,057 230;12/827;61 29.5 -41.3 to 64.8 47.5 -15 to 76.0
15–59 years 1,995 603;29/1,392;96 28.1 -17.1 to 55.9 43.2 5.2 to 66.0
 ≥60q years 611 132;34/479;208 53.5 24.1 to 71.5 54.1 22.4 to 72.8
Target group for vaccinationr 1,057 293;56/764;266 54.9 27.2 to 72.0 56.0 26.2 to 73.8
CI: confidence interval; DE: Germany; ES: Spain; HU: Hungary; IE: Ireland; I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe; IT: Italy; PL: Poland; PT: Portugal; 
RO: Romania; VE: vaccine effectiveness.
a Based on the complete case analysis: records with missing age, sex, chronic condition, vaccination status are dropped.
b Totals may differ between one-stage and two-stage models, as adjustment at study site-level may vary to the one-stage pooled model adjustment, resulting in different 
missing data dropped depending on included covariates. In addition different numbers of study sites may be included in each analysis due to sample size issues.
c Crude VE adjusted by study site.
d Data adjusted for age (restricted cubic spline), onset date (restricted cubic spline), sex, chronic condition and study site. Exceptions are A(H3N2) all ages, where age groups 
(0–4, 5–14, 15–59 and  ≥60 years) are used instead of restricted cubic splines.
e Study sites include DE, ES, IT. HU not included in the 0–14 year old analysis, as no patients included aged  <18 years. Sample size too low for IE, PT and RO.
f Study sites include DE, ES, HU, IE, IT, PT, RO. Sample size too low for PL. Crude VE for RO used in adjusted estimate, due to low sample size.
g Study sites include DE, ES, HU, IT, RO. IE, PL and PT not included due to low sample size. Crude VE for RO used in adjusted estimate, due to low sample size.
h Study sites include DE, ES, IE, IT, PL, PT, RO. HU not included in the 0–14 year old analysis, as no patients included aged  <18 years.
i Data adjusted for age (restricted cubic spline), onset date (restricted cubic spline), sex, chronic condition and study site. Exceptions the A(H1N1)pdm09 analysis among the 
elderly, where data are adjusted for age (restricted cubic spline), onset date (restricted cubic spline), and study site only.
j Study sites include DE, HU, IE, IT, RO, PL. ES and IE dropped from analysis due to small sample size.
k Study sites include DE, IT. ES, IE, PL, RO not included as sample size too low. HU not included in the 0–14 year old analysis, as no patients included aged <18 years.
l Study sites include DE, IT, RO. ES, HU, IE and PL not included as sample size too small. Crude VE for RO used in adjusted estimate, due to low sample size.
m Study sites include DE, IT. ES, HU, IE, PL and RO not included as sample size too small. Only crude VE available, due to low sample size.
n Study sites include DE, IT, RO. ES, HU, IE and PL not included as sample size too small. Crude VE for RO used in adjusted estimate, due to low sample size.
o Data adjusted for age (restricted cubic spline), onset date (restricted cubic spline), sex, chronic condition and study site. Exceptions the B analysis among the elderly, 
where data are adjusted for age (restricted cubic spline), onset date (restricted cubic spline), and study site only.
p Study sites include DE, ES, IT. IE, PL, PT and RO not included as sample size too low. HU not included in the 0–14 year old analysis, as no patients included aged < 18 years.
q Study sites include DE, ES, HU, IE, IT, PL, PT, RO. Crude VE for DE, HU, IE, PL and RO due to low sample size.
r Study sites include DE, ES, HU, IE, IT, PL, PT, RO. Crude VE for HU, IE and RO due to low sample size.
Table 3
Pooled crude and adjusted seasonal vaccine effectiveness against laboratory-confirmed influenza by influenza type/subtype, 
overall and by age groups, I-MOVE multicentre case–control study, Europe, influenza season 2014/15 (week 41/2014-week 
19/2015)
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mutations G5E and N31S. Twenty viruses belonged to 
the group 3C.3b represented by A/Newcastle/22/2014 
and characterised by T128A, R142G, N145S, E62K, 
K83R, N122D, L157S and R261Q mutations. Seven of 
these presented an additional amino acid change 
Q197H at the antigenic site B (Figure 4).
Twelve viruses belonged to the group 3C.3a that har-
bours the T128A, R142G, A138S, N145S, F159S and 
N225D mutations. Nine of them had an extra muta-
tion K276N at the antigenic site C. Fifty-eight viruses 
belonged to group 3C.2a and the only mutations identi-
fied were L3I, N144S, N145S, F159Y, K160T, N225D and 
Q311H - amino acid mutations that define the group.
Influenza A(H1N1)pdm09
The overall adjusted VE against influenza A(H1N1)
pdm09 was 54.2% (95% CI: 31.2 to 69.6) (Table 3).The 
adjusted VE was 73.1% (95% CI: 39.6 to 88.1) among 
the 0–14 year olds, 59.7% (95% CI: 10.9 to 81.8) among 
the 15–59 year olds and 22.4% (95% CI: -44.4 to 58.4) 
among those  ≥60 years of age.
By vaccine type, the adjusted VE point estimate was 
higher for the adjuvanted vaccine (79.8%) than for the 
egg-derived inactivated subunit and the inactivated 
split virion vaccines (53.0% and 51.5% respectively). 
We could not compute the VE for the cell-derived inac-
tivated subunit due to small numbers (7 controls vac-
cinated and no cases vaccinated) (Table 4).
The adjusted VE point estimate was lower (-1.9%) 
among those vaccinated in 2013/14 only compared 
with those vaccinated in 2014/15 only (47.2%) and to 
those vaccinated in both seasons (52.7%) (Table 4).
The overall adjusted VE point estimate did not vary 
when restricting the analysis to the target group for vac-
cination (53.6%), when excluding those vaccinated < 15 
days (54.5%) before symptom onset and when using a 
two-stage pooled model (53.5%). It was 61.0% when 
restricted to those swabbed less than 4 days of symp-
tom onset (Table 3).
Of the 539 A(H1N1)pdm09 viruses, 24 (4%) were geneti-
cally characterised and all belonged to the group 6B 
defined by the amino acid substitutions D97N, K163Q, 
S185T, S203T, A256T and K283E compared with A/
California/07/2009.
Influenza B
The overall adjusted VE against influenza B was 48.0% 
(95% CI: 28.9 to 61.9). The adjusted VE was 62.1% 
(95% CI: 14.9 to 83.1) among the 0–14 year olds, 41.4% 
(95% CI: 6.2 to 63.4) among the 15–59 year olds and 
50.4% (95% CI: 14.6 to 71.2) among those ≥60 years 
old (Table 3).
By vaccine type, the adjusted VE point estimates were 
lower for cell-derived inactivated subunit vaccines 
(16.0%) than for egg-derived subunit, split virion and 
adjuvanted vaccines (52.4%, 60.1%, 51.9% respec-
tively) (Table 4).
The adjusted VE point estimate was lower among those 
vaccinated only in 2013/14 (1.7%) than among those 
vaccinated only in 2014/15 (59.4%) or among those 
vaccinated in both seasons (43.8%) (Table 4).
There was less than 9% absolute difference between 
the overall adjusted VE point estimates and the VE 
in all sensitivity analyses (Table 3). The two-stage VE 
point estimate in the 0–14 years old was 15% lower 
than the one-stage VE point estimate but five study 
sites were excluded from the two-stage analysis due to 
their limited sample size.
Among 746 cases for which the lineage was available, 
740 (99.2%) were Yamagata and six Victoria.
One hundred and fifty-three (15%) of the 1,038 B 
viruses were characterised: 151 B Yamagata and 
two B Victoria viruses. Of the 151 B Yamagata line-
age viruses genetically characterised, 148 (98%) 
belonged to B/Phuket/3073/2013, clade 3 and three 
to B/Massachusetts/02/2012. The two B Victoria 
viruses genetically characterised belonged to B/
Brisbane/60/2008 (1A).
Discussion
The results of the I-MOVE multicentre case–control 
study suggest a low 2014/15 influenza VE against med-
ically attended ILI due to A(H3N2) and a moderate VE 
against medically attended ILI due to A(H1N1)pdm09 or 
B.
The sample size of the I-MOVE multicentre case–con-
trol study for the 2014/15 season was one of the larg-
est since 2008/09. We could estimate VE against the 
three circulating viruses. However, with the low influ-
enza vaccination coverage in the participating sites, we 
still have limited statistical power for some subgroup 
analyses that provide important information for pub-
lic health action like VE by previous vaccination or VE 
by type of vaccine. The current sample size is still too 
small to measure VE by vaccine product.
Measuring VE by study sites was not among the objec-
tives of our multicentre study. In addition, as in pre-
vious seasons, study sites, sample size pending, are 
publishing their own results. However, even if not 
statistically significant, VE may differ between study 
sites. Differences in site-specific adjusted VE may be 
explained, among other factors, by variability due to 
the limited number of samples, unknown residual con-
founding, or different vaccines used. In future seasons 
we are confident that, with more resources, sample 
sizes should increase allowing for better adjustment 
and stratification including by vaccine brand.
Integrating virological and epidemiological informa-
tion is essential to interpret VE estimates [5]. For the 
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Table 4
Pooled crude and adjusted seasonal vaccine effectiveness against laboratory- confirmed influenza by influenza type/
subtype, by vaccine type and by influenza vaccination status in 2013/14, I-MOVE multicentre case–control study, Europe, 
influenza season 2014/15 (week 41/2014-week 19/2015)
Influenza type/








Unvaccinated 3,901 1,498/2,403 Ref NA Ref NA
Egg-derived inactivated 
subunit 205 88/117 -5.7 -41.7 to 21.2 10.9
-24.3 to 
–36.1
Egg-derived inactivated split 
virion 164 56/108 -0.4 -41.2 to 28.6 18.6 -17.4 to 43.5
Adjuvanted 116 38/78 11.8 -32.7 to 41.4 14.0 -34.1 to 44.9
Cell-Derived inactivated 





Unknown 82 30/52 -12.0 -77.1 to 29.2 21.3 -29.7 to 52.3
By previous 
vaccination
Unvaccinated in both seasons 3,697 1,434/2,263 Ref NA Ref NA
Vaccinated in 2014/15 only 133 41/92 29.8 -2.7 to 52.0 43.7 15.3 to 62.5
Vaccinated in 2013/14 only 147 43/104 28.2 -3.4 to 50.2 0.0 -50.7 to 33.7




Unvaccinated 2,570 479/2,091 Ref NA Ref NA
Egg-derived inactivated 
subunit 113 10/103 47.1 -4.5 to 73.2 53.0 4.1 to 76.9
Egg-derived inactivated split 
virion 104 16/88 47.5 8.1 to 70.0 51.5 13.4 to 72.8
Adjuvanted 73 3/70 84.4 49.3.to.95.2 79.8 31.0.to.94.1
Cell-derived inactivated 
subunit 7 0/7 NA NA NA NA
Unknown 53 7/46 24.8 -70.7 to 66.8 35.3 -48.5 to 71.8
By previous 
vaccination
Unvaccinated in both seasons 2,438 459/1,979 Ref NA Ref NA
Vaccinated in 2014/15 only 90 10/80 46.6 -5.8 to 73.0 47.2 -7.1 to 74.0
Vaccinated in 2013/14 only 99 15/84 11.8 -56.8 to 50.4 -1.9
-86.2 to 
44.2




Unvaccinated 3,294 927/2,367 Ref NA Ref NA
Egg-derived inactivated 
subunit 146 27/119 49.3 20.7 to 67.6 52.4 22.9 to 70.6
Egg-derived Inactivated split 
virion 119 18/101 59.5 30.8 to 76.3 60.1 30.1 to 77.3
Adjuvanted 86 8/78 51.3 -4.1 to 77.2 51.9 -6.2 to 78.2
Cell-derived Inactivated 





Unknown 68 14/54 25.0 -40.7 to 60.0 27.3 -40.2 to 62.3
By previous 
vaccination
Unvaccinated in both seasons 3,127 894/2,233 Ref NA Ref NA
Vaccinated in 2014/15 only 107 14/93 61.1 29.8 to 78.4 59.4 25.1 to –78.0
Vaccinated in 2013/14 only 128 26/102 20.3 -26.6 to 49.8 1.7 -61.8 to 40.3
Vaccinated in both seasons 309 58/251 43.3 22.5 to 58.6 43.8 20.0 to 60.5
CI: confidence interval; Ref: reference; I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe; NA: not applicable; VE: vaccine effective-
ness.
a Based on the complete case analysis: records with missing age, sex, chronic condition, vaccination status are dropped).
b Crude VE adjusted by study site.
C Data adjusted for age (restricted cubic spline or age group), onset date (restricted cubic spline), sex, chronic condition and study site.
Note: Egg-derived inactivated subunit vaccines used in DE, IE, PO, PT, RO, ES.
Egg-derived inactivated Split virion vaccines used in DE, HU, IT, PO, PT, ES.
Adjuvanted vaccines used in DE, HU, IT, ES.
Cell-derived inactivated subunit vaccines used in Germany, ES.
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last two seasons, the I-MOVE multicentre case–con-
trol teams have made an effort to include genetic and 
antigenic results from a sample of the cases included 
in the study. However, the proportion of strains geneti-
cally and antigenically characterised (8.5%) is still low, 
and varied by site. Two study sites (Italy, Poland) could 
not provide results and some sites with a low number 
of cases characterised a higher proportion of viruses 
than sites with high number of cases. For instance, 11 
of the 17 clade 3C.3a viruses characterised were from 
Romania, a site that contributed to only 4.4% of the 
A(H3N2) cases. In addition, the viruses characterised 
were selected according to virological surveillance 
objectives (e.g. selection of viruses from more severe 
cases, from vaccinated cases, etc.). Due to the non-ran-
dom selection and the different proportion of viruses 
characterised we cannot exclude that the viruses char-
acterised may not be representative of the viruses from 
cases included in the study. For the 2015/16 season, 
the I-MOVE multicentre case–control study will pilot 
a selection procedure aiming to provide a representa-
tive sample of viruses characterised. If resources are 
available, the number of viruses characterised should 
increase.
The VE against influenza A(H3N2) was low overall, by 
age group and among the target group for vaccination. 
Four different genetic clades of A(H3N2) viruses (3C.2a, 
3C.3a, 3C.3 and 3C.3b) circulated in the eight countries 
participating in I-MOVE. The low VE are in concordance 
with the high proportion (66%) of 3C.2a and 3C.3a 
drifted viruses identified among those genetically 
characterised. Additional mutations were detected in 
the 3C.3 and 3C.3b influenza A(H3N2) viruses charac-
terised but those are considered antigenically simi-
lar to the vaccine virus [13]. This season, estimates 
are similar to the VE against A(H3N2) we observed in 
2011/12 and 2013/14 [8,9]. They are lower than the final 
2014/15 VE against A(H3N2) reported in the UK even 
if the proportion of drifted virus among those geneti-
cally characterised are higher in UK than in our study 
[14]. VE against A(H3N2) was below 20% for all vaccine 
types with a lower point estimate for the cell-derived 
subunit vaccine. The effectiveness was lower in those 
vaccinated in both 2013/14 and 2014/15 than in those 
vaccinated only in the 2014/15 season. These observa-
tions are in line with the results of the 2014/15 early 
A(H3N2) VE estimates in Canada [5] and with those 
observed in previous studies [15-17]. They are congru-
ent with the hypothesis that prior immunisation may 
decrease the effectiveness of the vaccine and that this 
negative interference is more important when the anti-
genic distance is small between successive vaccine 
components but large between vaccine and circulating 
strain [18]. These conditions were present in 2014/15 
with an unchanged A(H3N2) vaccine component com-
pared with the 2013/14 vaccine and with a mismatch 
between the vaccine and a high proportion of circu-
lating strains. However, those results may be due to 
chance, or to bias. We need a much larger sample size 
to have higher precision in the estimates and to study 
the effect of prior vaccinations by age group. In our 
study, individuals vaccinated in both seasons are older 
than those vaccinated only in one season (median age 
63 years and 50 years respectively). Unmeasured dif-
ferences between individuals vaccinated in two con-
secutive seasons and those vaccinated only in one 
season may have affected the results. Previous vacci-
nation was documented through GP records or patient 
self-reports and may be subject to error. Since neither 
the ILI patient nor the GPs knew if the patient was an 
influenza case we are confident that differential recall 
Table 5
Influenza A(H3N2), A(H1N1)pdm09, B Yamagata, B Victoria viruses characterised by clade and study site, I-MOVE 
multicentre case–control study, Europe, influenza season 2014/15 (week 41/2014-week 19/2015) (n=291)














A/HongKong/5738/2014 3C.2a 12 NA 11 14 2 19 58 (51)
A/Switzerland/9715293/2013 3C.3a NA NA 1 NA 11 5 17 (15)
A/Samara/73/2013 3C.3 5 NA 3 4 3 4 19 (17)
A/Newcastle/22/2014 3C.3b 5 2 1 NA 3 9 20 (17)
Total A(H3N2) NA 22 2 16 18 19 37 114 (100)
A(H1N1)pdm09 (n=24) 
A/SouthAfrica/3626/2013 6B 12 NA 5 2 5 NA 24 (100)
B Yamagata (n=151) 
B/Phuket/3073/2013 Clade 3 31 NA 5 56 28 28 148 (98)
B/Massachusetts/02/2012 Clade 2 NA NA NA 1 2 NA 3 (2)
Total B Yamagata NA 31 NA 5 57 30 28 151 (100)
B Victoria (n=2) 
B/Brisbane/60/2008 NA NA NA 2 NA NA NA 2 (100)
NA: not applicable.
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did not bias the results. If the results were not due to 
bias or to chance, concurrent immunological studies 
will be essential to better understand the biological 
mechanism behind, and the role of natural vs vaccine-
acquired immunity.
The VE estimates against influenza A(H1N1)pdm09 are 
similar to our results in previous seasons [7-9]. The 
laboratory results indicate that the strains isolated 
from study participants were similar to the A(H1N1)
pdm09 component of the 2014/15 influenza vaccine. As 
in 2013/14, we observed a lower VE among the elderly 
and higher among those aged 0–14 years old, however 
sample sizes were small in the age group analyses. The 
VE point estimates of the adjuvanted vaccines were 
higher but the small sample size in the analysis does 
not allow a comparison of effectiveness between vac-
cine types.
The VE against influenza B ranged from 41% to 62% 
in the overall population and was 56% in the target 
group for vaccination. Our estimates are similar to 
those reported by the UK [14]. Nearly all viruses (99%) 
for which lineage was available were B/Yamagata and 
98% of those characterised belonged to clade 3 that is 
antigenically similar to the vaccine virus. VE was simi-
lar by vaccine type with lower point estimate for cell-
derived inactivated subunit vaccines but the sample 
size is too low to interpret this observed difference. 
The results suggested no effect of the 2013/14 vaccine 
and a slightly lower VE among those vaccinated in both 
seasons.
This is the third season we provide VE by vaccine 
type. A high proportion of vaccinated study partici-
pants (84%) had vaccine product documented. Even 
with one of the largest sample size since 2008/09, the 
numbers are still too low to measure adjusted VE by 
vaccine type and age group. The European Medicines 
Agency (EMA) requests that vaccine producers provide 
product-specific vaccine effectiveness [19]. Taking into 
account the high number of vaccine products and the 
low vaccination coverage in countries participating in 
the study [20] the sample size to measure VE by vac-
cine product with high precision has to be much larger 
and substantial additional resources are needed. In a 
survey among I-MOVE partners to assess the feasibil-
ity of conducting product-specific VE in Europe (data 
not shown) most experts considered that in terms of 
resources allocation, providing precise estimates early 
in the season, by age group, by previous vaccination 
were of higher priority than measuring VE by product.
In summary, the 2014/15 results suggest a moderate 
effectiveness against influenza A(H1N1)pdm09 and B. 
The low effectiveness of the influenza vaccines against 
A(H3N2) observed again this season underlines the 
need to improve the A(H3N2) component of the vaccine 
especially among the target group for vaccination. This 
would be even more important if the observed negative 
effect of previous vaccination was confirmed. Since 
A(H3N2) virus is generally associated with more severe 
disease in the elderly and high-risk groups [21,22] and 
the vaccine is less effective against this influenza sub-
type, in seasons of A(H3N2) circulation early antiviral 
treatment should be recommended in these groups 
[3,6].
The effect of previous vaccinations is one of the ques-
tions that I-MOVE and other influenza VE teams in the 
US, Canada and Australia started to raise some years 
ago [17,24-27]. This is an important issue that may 
impact vaccination policy in Europe. They need to be 
addressed through international collaboration, a mul-
tidisciplinary approach and with long-term scientific 
independent studies. The I-MOVE multicentre case–
control study should continue to increase the sample 
size and to strengthen the virological component of the 
study to contribute to answer these questions.
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